发明申请
US20100074945A1 MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES
审中-公开
用于产生CD8 + CYTOTOXIC T淋巴细胞的突变RAP肽
- 专利标题： MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES
- 专利标题（中）： 用于产生CD8 + CYTOTOXIC T淋巴细胞的突变RAP肽
-
申请号： US12623062申请日： 2009-11-20
-
公开(公告)号： US20100074945A1公开(公告)日： 2010-03-25
- 发明人: Jeffrey Schlom , Scott Abrams
- 申请人： Jeffrey Schlom , Scott Abrams
- 申请人地址： US MD Bethesda
- 专利权人： The United States of America, as represented by,the Secretary, Department of Health and Human Services
- 当前专利权人： The United States of America, as represented by,the Secretary, Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 主分类号： A61K9/127
- IPC分类号： A61K9/127 ; C07K7/06 ; C07K7/08 ; A61K38/08 ; A61K38/10 ; A61K35/12 ; A61K38/20 ; A61K38/21 ; A61K38/16 ; C12N5/00 ; A61P35/00 ; C07H21/00 ; C12N15/63
摘要：
Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8+ CTL precursors.
公开/授权文献
信息查询
